Eisai Co., Ltd.: Breast Neoplasms trials

The registry lists 34 Breast Neoplasms studies with Eisai Co., Ltd. as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 1 8Phase 2 16Phase 3 3Phase 4 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast CancerActive, not recruitingNCT04288089Phase 1Results posted
• Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerCompletedNCT03250676Phase 1/2Results posted
• Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)TerminatedNCT02753595Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerCompletedNCT02481050Phase 2Results posted
• Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast CancerCompletedNCT01961544Phase 4Results posted
• Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast CancerCompletedNCT01439282Phase 2Results posted
• A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast CancerCompletedNCT01432886Phase 1Results posted
• Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast CancerCompletedNCT01328249Phase 2Results posted
• A Confirmation Study of Eribulin in Combination With CapecitabineCompletedNCT01323530Phase 1/2Results posted
• Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast CancerCompletedNCT01269346Phase 2Results posted
• A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast CancerCompletedNCT01268150Phase 2Results posted
• Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed TherapiesCompletedNCT01142661Not applicableResults posted
• Study of E7389 for Advanced or Metastatic Breast CancerCompletedNCT00965523Phase 2Results posted
• A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerCompletedNCT00879086Phase 2Results posted
• E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00388726Phase 3Results posted
• E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesCompletedNCT00337103Phase 3Results posted
• A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and CapecitabineCompletedNCT00246090Phase 2Results posted
• A Study of E7389 in Advanced/Metastatic Breast Cancer PatientsCompletedNCT00097721Phase 2Results posted
• A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast CancerCompletedNCT06188559Phase 2
• A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1
• Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT04568902Phase 1
• A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerCompletedNCT03583944Phase 4
• A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer ParticipantsCompletedNCT03437083
• Eribulin [Halaven] Use For the Treatment of Advanced Breast CancerCompletedNCT02790320
• Extended Treatment in Metastatic Breast Cancer With EribulinCompletedNCT02769364
• Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational RegistryCompletedNCT02443428
• Halaven Post-Marketing Surveillance (PMS)CompletedNCT02441764
• Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.CompletedNCT02371174
• Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesCompletedNCT02225470Phase 3
• Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)CompletedNCT01463891
• An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer RefractoryApproved for marketingNCT01240421
• An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With CapecitabineTerminatedNCT00165880Phase 2
• Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer PatientsCompletedNCT00080197Phase 2